|Bid||31.77 x 3200|
|Ask||33.83 x 800|
|Day's Range||31.51 - 32.99|
|52 Week Range||11.12 - 32.99|
|Beta (3Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.00|
Investors will be focused on a potentially trajectory-altering product launch, but it will be several quarters (at least) before we can start drawing conclusions about its impact.
nCounter Mouse AD Gene Expression Panel Applied to Characterize Five Novel Mouse Models New nCounter Human AD Gene Expression Panel Launched at AAIC 2019 SEATTLE, July.
SEATTLE, July 10, 2019 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today.
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and recouped their losses by the end of the first quarter. […]
NanoString Technologies, Inc. (NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced a publication in the journal Clinical Cancer Research of a collaborative research study led by investigators from the Yale School of Medicine. This paper represents the fourth peer-reviewed publication to describe GeoMx DSP.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Gov. Inslee has raised $2.3 million this year, with more than $1 million of that coming from donors in the Evergreen State.
SEATTLE, May 30, 2019 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products,.
Business Journal Managing Editor Rob Johnson takes readers through a recap of Seattle business news. We call it Business Journal Untucked.
SEATTLE, May 15, 2019 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products,.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
NanoString (NSTG) delivered earnings and revenue surprises of -6.15% and 8.91%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
SEATTLE (AP) _ NanoString Technologies Inc. (NSTG) on Thursday reported a loss of $21.9 million in its first quarter. On a per-share basis, the Seattle-based company said it had a loss of 69 cents. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 65 cents per share.
SEATTLE, May 09, 2019 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today.
Business Journal Managing Editor Rob Johnson takes readers for a casual tour of the week that was. We call it Business Journal Untucked.
Anticipated growth across core business unit and solid show by Medical Surgical and European Pharmaceutical Solutions is likely to aid McKesson's (MCK) Q4 earnings. However, rising costs might be a dampener.
Better-than-expected performance at Pharmaceutical and Medical segments and diverse product portfolio is likely to aid Cardinal Health (CAH) in Q3 earnings. However, stiff competition might play spoilsport.
NanoString (NSTG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Better-than-expected performance at Kidney Care, strategic buyouts and international expansion might aid DaVita (DVA) in Q1. However, integration risks might be a dampener.
Within Pharmacy Services, despite a fierce pricing competition, CVS Health (CVS) is currently riding on high level of service and execution, competitive pricing and a unique integrated model.